Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr 14;106(15):6268-72.
doi: 10.1073/pnas.0901185106. Epub 2009 Mar 30.

A multi-marker assay to distinguish malignant melanomas from benign nevi

Affiliations

A multi-marker assay to distinguish malignant melanomas from benign nevi

Mohammed Kashani-Sabet et al. Proc Natl Acad Sci U S A. .

Abstract

The histopathological diagnosis of melanoma can be challenging. No currently used molecular markers accurately distinguish between nevus and melanoma. Recent transcriptome analyses have shown the differential expression of several genes in melanoma progression. Here, we describe a multi-marker diagnostic assay using 5 markers (ARPC2, FN1, RGS1, SPP1, and WNT2) overexpressed in melanomas. Immunohistochemical marker expression was analyzed in 693 melanocytic neoplasms comprising a training set (tissue microarray of 534 melanomas and nevi), and 4 independent validation sets: tissue sections of melanoma arising in a nevus; dysplastic nevi; Spitz nevi; and misdiagnosed melanocytic neoplasms. Both intensity and pattern of expression were scored for each marker. Based on the differential expression of these 5 markers between nevi and melanomas in the training set, a diagnostic algorithm was obtained. Using this algorithm, the lesions in the validation sets were diagnosed as nevus or melanoma, and the results were compared with the known histological diagnoses. Both the intensity and pattern of expression of each marker were significantly different in melanomas compared to nevi. The diagnostic algorithm exploiting these differences achieved a specificity of 95% and a sensitivity of 91% in the training set. In the validation sets, the multi-marker assay correctly diagnosed a high percentage of melanomas arising in a nevus, Spitz nevi, dysplastic nevi, and misdiagnosed lesions. The multi-marker assay described here can aid in the diagnosis of melanoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: M.K.-S. has stock in Melanoma Diagnostics, Inc. J.R.M. has ownership interest in MDMS.

Figures

Fig. 1.
Fig. 1.
Photomicrographs of WNT2 immunostaining in a benign nevus (A), melanoma (B), and melanoma arising in association with a nevus (C), where M represents the melanoma and N represents the nevus.
Fig. 2.
Fig. 2.
ROC plots in the diagnosis of melanoma using marker intensity scores for 1 marker alone (FN1, curve 1), 3 markers (FN1, ARPC2, SPP1, curve 2), and all 5 markers (curve 3).
Fig. 3.
Fig. 3.
Diagnostic algorithm obtained from the training data and applied to the validation sets based on marker intensity scores as well as top-to-bottom differences. For each diagnostic statement in the algorithm the number of correct and incorrect diagnoses achieved in the training set are indicated.

References

    1. Jemal A, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Crowson AN, Magro CM, Mihm MC., Jr . The Melanocytic Proliferations. New York: Wiley-Liss; 2001. Chapter 10.
    1. Piepkorn MW, et al. A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol. 1994;30:707–714. - PubMed
    1. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 1996;27:528–531. - PubMed
    1. Corona R, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol. 1996;14:1218–1223. - PubMed

Publication types

Substances